Aprea Therapeutics to Present at EORTC-NCI-AACR Molecular Targets Conference

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical firm headquartered in Doylestown, Pennsylvania, is advancing its mission in precision oncology through synthetic lethality. The company, which trades on Nasdaq under the ticker symbol APRE, announced the acceptance of four abstracts for presentation at the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, scheduled for October 23-25, 2024.

The symposium is a prestigious event that focuses on the latest advancements in cancer research, providing a platform for sharing significant developments in molecular targets and cancer therapeutics. Aprea Therapeutics aims to showcase key progress in its oncology pipeline, particularly its DNA damage response (DDR) inhibitors, at this event.

Oren Gilad, Ph.D., the President and Chief Executive Officer of Aprea, expressed enthusiasm about the opportunity to present at the symposium. He emphasized the significance of the event as a venue for updating the international oncology community on the company's clinical-stage candidates, APR-1051 and ATRN-119.

The details of the posters to be presented are as follows:

1. Clinical Poster on APR-1051:
- Title: "Safety and Preliminary Efficacy of APR-1051, a WEE1 Inhibitor, in a Phase 1 Study of Patients with Cancer-Associated Gene Alterations (ACESOT-1051)"
- Date/Time: Wednesday, October 23rd, 12:00 - 19:00 CET
- Location: Exhibition Hall
- Poster Number: 77

2. Clinical Poster on ATRN-119:
- Title: "ATRN-119, a Novel Macrocyclic ATR Inhibitor, in Patients with Advanced Solid Malignancies: A Phase 1/2a Trial (ABOYA-119)"
- Date/Time: Friday, October 25th, 09:00 - 15:00 CET
- Location: Exhibition Hall
- Poster Number: 348

3. Preclinical Poster on APR-1051:
- Title: "The novel WEE1i, APR-1051, does not substantially off-target PLK1, PLK2, or PLK3 and exhibits favorable in vivo characteristics for treating CCNE1-overexpressing cancers"
- Date/Time: Friday, October 25th, 09:00 - 15:00 CET
- Location: Exhibition Hall
- Poster Number: 335

4. Preclinical Poster on Macrocyclic ATR Inhibitors:
- Title: "Development and testing of a first-in-class series of macrocyclic ATR inhibitors for cancer treatment"
- Date/Time: Friday, October 25th, 09:00 - 15:00 CET
- Location: Exhibition Hall
- Poster Number: 336

After the symposium, copies of the posters will be accessible on the “Investor Resources” page of Aprea's corporate website.

Aprea Therapeutics' lead program, ATRN-119, is a clinical-stage small molecule ATR inhibitor aimed at treating solid tumors. In addition, the company's APR-1051, a novel oral WEE1 inhibitor, has recently entered the clinical trial phase. Both candidates represent significant advancements in the field of synthetic lethality, a promising area in oncology that targets cancer cells' ability to repair DNA damage, thereby enhancing the effectiveness of cancer treatments.

Aprea Therapeutics continues to focus on precision oncology, leveraging synthetic lethality to develop targeted cancer therapies. By presenting its latest research at the EORTC-NCI-AACR Symposium, the company aims to share its progress with the global scientific community, fostering collaborations and advancing the development of novel cancer treatments.

For more information about Aprea Therapeutics and their ongoing projects, interested parties are encouraged to visit the company’s website.